Altre lingue Fennec Pharmaceuticals Inc.

Azioni

FENC

CA31447P1009

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 17/04/2024			Variaz. 5gg	Var. 1 gen.
9,7 ^USD	-5,46%		-9,09%	-13,55%

17/04	Un insider di Fennec Pharmaceuticals ha venduto azioni per un valore di 457.182 dollari, secondo un recente documento della SEC	MT
05/04	L'insider di Fennec Pharmaceuticals ha venduto azioni per un valore di 958.669 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	17/04
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	05/04
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	03/04
Wedbush on Fennec's Q4	21/03
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	21/03
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	21/03
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	21/03
North American Morning Briefing : Investors -2-	21/03
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	21/03
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	19/03
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024	19/03
Wedbush on Fennec's Deal for Pedmarqsi in EU	18/03
Sector Update: Health Care Stocks Steady Premarket Monday	18/03
Sector Update: Health Care	18/03
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	18/03
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	18/03
Fennec Pharmaceuticals Signs Exclusive Licensing Deal With Norgine	18/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Fennec Pharmaceuticals Inc.

Azioni

FENC

CA31447P1009

Altre lingue

Filtri